SUPPLEMENTARY ONLINE CONTENT

Supplement to: Krzysztof Selmaj, Frederik Barkhof, Anna Belova, et al. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results

This appendix has been provided by the authors to give readers additional information about their work.

Supplemental Table e-1

Adverse events reported for ≥1% of subjects in the GTR/GTR group or GA/GTR group or for more than two subjects in the PLC/GTR group summarized by MedDRA SOC and PT (open-label part - Safety Set)

Event classified by System Organ Class Preferred Term – no. (%) of patients	**GTR/GTR (N=324) n (%)**	**GA/GTR (N=323) n (%)**	**Placebo/GTR (N=81) n (%)**	**Total (N=728) n (%)**
Any event	**108(33.3%)**	**118(36.5%)**	**35(43.2%)**	**261(35.9%)**
Infections and infestations	**40(12.3%)**	**51(15.8%)**	**16(19.8%)**	**107(14.7%)**
Nasopharyngitis	15(4.6%)	16(5.0%)	8(9.9%)	39(5.4%)
Bronchitis	4(1.2%)	2(0.6%)	0(0.0%)	6(0.8%)
Respiratory tract infection viral	4(1.2%)	1(0.3%)	1(1.2%)	6(0.8%)
Influenza	2(0.6%)	4(1.2%)	0(0.0%)	6(0.8%)
Rhinitis	2(0.6%)	4(1.2%)	0(0.0%)	6(0.8%)
Urinary tract infection	1(0.3%)	6(1.9%)	1(1.2%)	8(1.1%)
General disorders and administration site conditions	**31(9.6%)**	**27(8.4%)**	**12(14.8%)**	**70(9.6%)**
Asthenia	7(2.2%)	2(0.6%)	0(0.0%)	9(1.2%)
Immediate post-injection reaction	7(2.2%)	3(0.9%)	1(1.2%)	11(1.5%)
Injection site reaction	4(1.2%)	3(0.9%)	8(9.9%)	15 (2.1%)
Injection site pain	1(0.3%)	5(1.5%)	1(1.2%)	7(1.0%)
Nervous system disorders	**31(9.6%)**	**28(8.7%)**	**7(8.6%)**	**66(9.1%)**
Headache	9(2.8%)	5(1.5%)	2(2.5%)	16(2.2%)
Multiple sclerosis relapse	5(1.5%)	6(1.9%)	1(1.2%)	12(1.6%)
Musculoskeletal and connective tissue disorders	**17(5.2%)**	**11(3.4%)**	**5(6.2%)**	**33(4.5%)**
Back pain	7(2.2%)	3(0.9%)	0(0.0%)	10(1.4%)

Event classified by System Organ Class Preferred Term – no. (%) of patients	GTR/GTR (N=324) n (%)	GA/GTR (N=323) n (%)	Placebo/GTR (N=81) n (%)	Total (N=728) n (%)
Investigations	**11 (3.4%)**	**5 (1.5%)**	**1 (1.2%)**	**17 (2.3%)**
Renal and urinary disorders	**9 (2.8%)**	**5 (1.5%)**	**1 (1.2%)**	**15 (2.1%)**
Gastrointestinal disorders	**8 (2.5%)**	**14 (4.3%)**	**1 (1.2%)**	**23 (3.2%)**
Injury, poisoning and procedural complications	**7 (2.2%)**	**6 (1.9%)**	**3 (3.7%)**	**16 (2.2%)**
Reproductive system and breast disorders	**7 (2.2%)**	**5 (1.5%)**	**2 (2.5%)**	**14 (1.9%)**
Blood and lymphatic system disorders	**6(1.9%)**	**8(2.5%)**	**1(1.2%)**	**15(2.1%)**
Anemia	4(1.2%)	3(0.9%)	1(1.2%)	8(1.1%)
Psychiatric disorders	**6(1.9%)**	**10(3.1%)**	**3(3.7%)**	**19(2.6%)**
Anxiety	0(0.0%)	4(1.2%)	1(1.2%)	5(0.7%)
Skin and subcutaneous tissue disorders	**5 (1.5%)**	**9 (2.8%)**	**1 (1.2%)**	**15 (2.1%)**
Cardiac disorders	**4 (1.2%)**	**1 (0.3%)**	**1 (1.2%)**	**5 (0.7%)**
Ear and labyrinth disorders	**4 (1.2%)**	**2 (0.6%)**	**0 (0.0%)**	**6 (0.8%)**
Metabolism and nutrition disorders	**3 (0.9%)**	**5 (1.5%)**	**0 (0.0%)**	**10 (1.4%)**
Neoplasms benign, malignant and unspecified (including cysts and polyps)	**3 (0.9%)**	**5 (1.5%)**	**2 (2.5%)**	**9 (1.2%)**
Respiratory, thoracic and mediastinal disorder	**3 (0.9%)**	**7 (2.2%)**	**1 (1.2%)**	**13 (1.8%)**
Vascular disorders	**3 (0.9%)**	**8 (2.5%)**	**3 (3.7%)**	**12 (1.6%)**
Eye disorders	**2 (0.6%)**	**2 (0.6%)**	**1 (1.2%)**	**5 (0.7%)**
Hepatobilary disorders	**2 (0.6%)**	**1 (0.3%)**	**0 (0.0%)**	**3 (0.4%)**
Immune system disorders	**1 (0.3%)**	**1 (0.3%)**	**2 (2.5%)**	**4 (0.5%)**
Endocrine disorders	**0 (0.0%)**	**1 (0.3%)**	**0 (0.0%)**	**1 (0.1%)**

Event classified by System Organ Class Preferred Term – no. (%) of patients	GTR/GTR (N=324) n (%)	GA/GTR (N=323) n (%)	Placebo/GTR (N=81) n (%)	Total (N=728) n (%)
Surgical and medical procedures	**0 (0.0%)**	**1 (0.3%)**	**0 (0.0%)**	**1 (0.1%)**

Supplemental Figure e-1

Design of the GATE trial.



Supplemental Figure e-2

Frequency distribution of local injection site reaction scores (safety population)

Patients completed a diary for 14 consecutive days at the initiation of open-label treatment (Panels A and B) and month 12 (Panels C and D), recording which of five injection site symptoms (pain, itchiness, redness, swelling, or lumps) were present after 5 minutes (Panels A and C) or 24 hours (Panels B and D). The local injection site reaction score represents the number (from 0 to 5) of symptoms present. GA = brand glatiramer acetate, GTR = generic glatiramer acetate, LISR = Local injection site reaction.


GTR/GTR
GA/GTR
PLC/GTR
A
B
C
D
Patients (%) with LISR score
Days
NA
0
1
2
3
4
5